Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin versus sevelamer for hyperphosphatemia in hemodialysis patients
IRCT20190324043106N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Jun 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of niacin and sevelamer carbonate in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoints: Serum phosphorus level, Serum calcium level and 1 more. Started Jun 2019; status: completed.
02
Drugs
niacinsevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20190324043106N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190324043106N1.